1. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Issue 8 (4th June 2020) Authors: Bayraktar, Soley; Zhou, Jade Z.; Bassett, Roland; Gutierrez Barrera, Angelica M.; Layman, Rachel M.; Valero, Vicente; Arun, Banu Journal: Breast journal Issue: Volume 26:Issue 8(2020) Page Start: 1572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer. (6th February 2022) Authors: Layman, Rachel M.; Lin, Heather; Gutierrez Barrera, Angelica M.; Karuturi, Meghan S.; Yam, Clinton; Arun, Banu K. Journal: Cancer medicine Issue: Volume 11:Number 6(2022) Page Start: 1474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Inclusion of premenopausal women in breast cancer clinical trials. (December 2022) Authors: Corrigan, Kelsey L.; Kouzy, Ramez; Jaoude, Joseph Abi; Patel, Roshal R.; Layman, Rachel M.; Giordano, Sharon H.; Woodward, Wendy A.; Smith, Benjamin D.; Shaitelman, Simona F.; Ludmir, Ethan B. Journal: Breast Issue: Volume 66(2022) Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis. (1st January 2021) Authors: Lin, Jamie S.; Mamlouk, Omar; Selamet, Umut; Tchakarov, Amanda; Glass, William F.; Sheth, Rahul A.; Layman, Rachel M.; Dadu, Ramona; Abdel-Wahab, Noha; Abdelrahim, Maen; Diab, Adi; Yee, Cassian; Abudayyeh, Ala Journal: Oncoimmunology Issue: Volume 10:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis. (1st January 2021) Authors: Lin, Jamie S.; Mamlouk, Omar; Selamet, Umut; Tchakarov, Amanda; Glass, William F.; Sheth, Rahul A.; Layman, Rachel M.; Dadu, Ramona; Abdelwahab, Noha; Abdelrahim, Maen; Diab, Adi; Yee, Cassian; Abudayyeh, Ala Journal: Oncoimmunology Issue: Volume 10:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study. Issue 12 (3rd March 2022) Authors: Ha, Min Jin; Singareeka Raghavendra, Akshara; Kettner, Nicole M.; Qiao, Wei; Damodaran, Senthil; Layman, Rachel M.; Hunt, Kelly K.; Shen, Yu; Tripathy, Debu; Keyomarsi, Khandan Journal: International journal of cancer Issue: Volume 150:Issue 12(2022) Page Start: 2025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations. Issue 1 (January 2021) Authors: Layman, Rachel M.; Arun, Banu Journal: Cancer journal Issue: Volume 27:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study. (17th June 2020) Authors: Wesolowski, Robert; Stover, Daniel G.; Lustberg, Maryam B.; Shoben, Abigail; Zhao, Meng; Mrozek, Ewa; Layman, Rachel M.; Macrae, Erin; Duan, Wenrui; Zhang, Jun; Hall, Nathan; Wright, Chadwick L.; Gillespie, Susan; Berger, Michael; Chalmers, Jeffrey J.; Carey, Alahdra; Balasubramanian, Priya; Mill... Journal: Oncologist Issue: Volume 25:Number 8(2020) Page Start: e1158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗